

# Gene expression in bladder cancer and normal tissues

<b>Submission date</b> 21/12/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 26/02/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 06/01/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

In this study, patients with bladder cancer were examined to analyze the levels of RBM15 in both cancerous and normal tissues. The goal was to identify potential therapeutic targets that could be used to treat bladder cancer more effectively.

### Who can participate?

Patients diagnosed with bladder cancer

### What does the study involve?

Participants joined the study starting in March 2018 and for 6 years. This study collects tissue samples at the time of surgery and follows participants for 6 years. Patients are followed up annually by telephone for survival. Cancerous and normal tissues were collected from patients with bladder cancer.

### What are the possible benefits and risks of participating?

The study team provided 1000 RMB as compensation for each patient. In this study, the discarded tumor tissue was removed during the patient's operation, which did not affect the body and no other participation risks were anticipated.

### Where is the study run from?

The study was conducted in Affiliated Haikou Hospital of Xiangya Medical College

### When is the study starting and how long is it expected to run for?

March 2022 to June 2024

### Who is funding the study?

1. Finance Science and Technology Project of Hainan Province
2. National Science Foundation of China
3. Health Department of Hainan Province

### Who is the main contact?

Shufang Zhang, zsf\_99900023@csu.edu.cn

## Contact information

### Type(s)

Public, Scientific, Principal investigator

### Contact name

Prof Shufang Zhang

### ORCID ID

<https://orcid.org/0009-0000-7203-665X>

### Contact details

No.43 Renmin Avenue

Haikou

China

570208

+86 089866289665

zsf\_99900023@csu.edu.cn

### Type(s)

Public, Principal investigator

### Contact name

Dr Mei Chen

### Contact details

No.43 Renmin Avenue

Haikou

China

570208

+86 15243653187

meichen\_cns@163.com

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### Protocol serial number

CPMS2023

## Study information

### Scientific Title

Bladder cancer and normal tissues

### Study objectives

Expression of RBM15 in bladder cancer and normal tissue

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

approved 10/03/2022, Haikou Municipal People's Hospital Biomedical Ethics Committee (No.43 Renmin Avenue, Haikou, 570208, China; +86 089866189665; zsf66189665@126.com), ref: 2023-055

**Study design**

Observational cohort study

**Primary study design**

Observational

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Bladder cancer

**Interventions**

This study enrolls patients with bladder cancer, collects tissue samples at the time of surgery, and follows them for 6 years. Patients are followed up annually by telephone for survival.

Cancerous and normal tissues were collected from patients with bladder cancer.

**Intervention Type**

Other

**Primary outcome(s)**

Survival measured using data collected at an annual telephone call for 6 years

**Key secondary outcome(s)**

Transfer or not measured using data collected during a telephone call every 6 months

**Completion date**

12/06/2024

**Eligibility****Key inclusion criteria**

Patients who were diagnosed with bladder cancer

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Sex**

All

**Key exclusion criteria**

Patients with other cancers

**Date of first enrolment**

11/05/2022

**Date of final enrolment**

01/06/2024

## Locations

**Countries of recruitment**

China

**Study participating centre**

**Affiliated Haikou Hospital of Xiangya Medical College**

No.43 Renmin Avenue

Haikou

China

570208

## Sponsor information

**Organisation**

Affiliated Haikou Hospital of Xiangya Medical College

## Funder(s)

**Funder type**

Government

**Funder Name**

Hainan Provincial Department of Science and Technology

**Alternative Name(s)**

, Department of Science and Technology of Hainan Province

**Funding Body Type**

Government organisation

**Funding Body Subtype**

Local government

**Location**

China

**Funder Name**

National Natural Science Foundation of China

**Alternative Name(s)**

Chinese National Science Foundation, Natural Science Foundation of China, National Science Foundation of China, NNSF of China, NSF of China, National Nature Science Foundation of China, Guójiā Zìrán Kēxué Jījīn Wěiyuánhùi, , NSFC, NNSF, NNSFC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

China

**Funder Name**

Hainan Provincial Department of Health

**Alternative Name(s)**

, Department of Health, Hainan Province, Hainan Health Department

**Funding Body Type**

Government organisation

**Funding Body Subtype**

Local government

**Location**

China

## Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Shufang Zhang, zsf\_99900023@csu.edu.cn

**IPD sharing plan summary**

Available on request